Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

NCT ID: NCT01932476

Last Updated: 2017-04-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the immune response causing celiac disease is related to the autoimmune response causing type-1 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants meeting eligibility criteria will have blood collected before and after a three-day oral gluten challenge. This blood will be tested for biomarkers associated with islet autoimmunity and gluten-specific cellular immunity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Celiac Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Celiac Disease Alone Gluten Challenge

Group Type EXPERIMENTAL

Gluten Challenge

Intervention Type DIETARY_SUPPLEMENT

Three-day gluten containing dietary challenge.

Celiac Disease Alone Sham Challenge

Group Type SHAM_COMPARATOR

Sham Challenge

Intervention Type DIETARY_SUPPLEMENT

Three-day sham (gluten free) dietary challenge

Celiac Disease and T1D Gluten Challenge

Group Type EXPERIMENTAL

Gluten Challenge

Intervention Type DIETARY_SUPPLEMENT

Three-day gluten containing dietary challenge.

Celiac Disease and T1D Sham Challenge

Group Type SHAM_COMPARATOR

Sham Challenge

Intervention Type DIETARY_SUPPLEMENT

Three-day sham (gluten free) dietary challenge

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gluten Challenge

Three-day gluten containing dietary challenge.

Intervention Type DIETARY_SUPPLEMENT

Sham Challenge

Three-day sham (gluten free) dietary challenge

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Celiac Disease by histology and serology
* For those with Type-1 Diabetes, at least one anti-islet antibody
* HLA-DQ2.5 genotype

Exclusion Criteria

* Not following a gluten free diet for at least 12 months
* Known gluten exposure within the prior 2 months
* Treatment with systemic immune modifying biological agents (adalimumab, etanercept, infliximab, certolizumab pegol) in prior 6 months
* Treatment with systemic immunomodulatory agents in prior 30 days
* Human immunodeficiency virus infection, untreated hepatitis B virus, or hepatitis C virus infection
* Nut allergy
* Hemoglobin level below normal range
* History of angina
* Pregnant or lactating
* Severe symptoms to gluten challenge in the past
* Elevation in transglutaminase-IgA or deamidated gliadin peptide IgA or IgG greater than or equal to 50% above upper limit of normal
* Uncontrolled complications of type-1 diabetes or celiac disease which pose a risk to participation
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ImmusanT, Inc.

INDUSTRY

Sponsor Role collaborator

Joslin Diabetes Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jason Gaglia

Assistant Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jason Gaglia, MD, MMSc

Role: PRINCIPAL_INVESTIGATOR

Joslin Diabetes Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Joslin Diabetes Center

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GC001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Latiglutenase in T1D/CD Patients
NCT04839575 TERMINATED PHASE2
Gluten Challenge in Celiac Disease
NCT02464150 COMPLETED NA